⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506998 | 1.00 | — | — | |
| SCHEMBL1768568 | 0.80 | — | — | |
| SCHEMBL13573831 | 0.80 | — | — | |
| SCHEMBL936930 | 0.72 | — | — | |
| SCHEMBL5711927 | 0.72 | — | — | |
| SCHEMBL1013212 | 0.72 | — | — | |
| SCHEMBL724770 | 0.72 | — | — | |
| SCHEMBL29614877 | 0.72 | — | — | |
| SCHEMBL29605286 | 0.71 | — | — | |
| SCHEMBL70747 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676922-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024189488-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | ASTRAZENECA AB (SE) | 2024-09-19 | — | — | WO | disclosed |
| US-20240190879-A1 | FUSED BICYCLIC COMPOUNDS USEFUL FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2024-06-13 | — | — | US | disclosed |
| CN-117756836-A | Heteroaryl compound containing boron, nitrogen and silicon, organic electroluminescent device and display device | 阜阳欣奕华材料科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230357209-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING DEVICE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT-EMITTING DEVICE | LT MATERIALS CO., LTD. (KR) | 2023-11-09 | — | — | US | disclosed |
| US-20230357209-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING DEVICE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT-EMITTING DEVICE | LT MATERIALS CO., LTD. (KR) | 2023-11-09 | — | — | US | disclosed |
| EP-4238969-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING DEVICE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT-EMITTING DEVICE | LT Materials Co., Ltd. (KR) | 2023-09-06 | — | — | EP | disclosed |
| EP-4221756-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2023-08-09 | — | — | EP | disclosed |
| CN-116249554-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023008795-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, AND COMPOSITION FOR ORGANIC LAYER | 엘티소재주식회사 | 2023-02-02 | — | — | WO | disclosed |
| EP-4110785-A1 | FUSED BICYCLIC COMPOUNDS USEFUL FOR MODULATING NUCLEIC ACID SPLICING | Remix Therapeutics Inc. (US) | 2023-01-04 | — | — | EP | disclosed |